

# Therapeutic Update



---

## Message from Lise Kjems, MD Chief Medical Officer at Cyclo Therapeutics

Dear NNPDF Community,

Having recently returned from the WORLDSymposium™, I am energized by the discussions and progress across lysosomal storage disorders, and particularly for the Niemann-Pick community. I had the opportunity at the meeting to present a poster about our Phase 3 trial, known as TransportNPC™. This pivotal clinical trial was designed in close collaboration with regulatory agencies, Key Opinion Leaders, patient advocacy groups and patient communities to best enable a potentially positive outcome. With the severity of this disease and the limited treatment options currently available to patients, there is a significant unmet need for a product that can treat the systemic and neurologic manifestations of NPC.



We continue to be encouraged by the potential of Trappsol® Cyclo™ and are leveraging this critical product, its mechanism of action and route of administration with the hope of providing a much-needed clinical benefit to the NPC patient population. Additionally, very recently, we established a global steering committee, led by the Principal Investigator for our TransportNPC study, Dr. Caroline Hastings, to shepherd our study forward. I am grateful to Dr. Hastings and to each member of this committee for their tireless effort to improve the lives of those living with NPC. You can read our full announcement [here](#).

For more information about the Company's [TransportNPC™](#) pivotal Phase 3 study, visit [ClinicalTrials.gov](#) and reference identifier [NCT04860960](#).

---

[www.cyclotherapeutics.com](http://www.cyclotherapeutics.com)